Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by T. Boyarskaya
Pcn73 - Budget Impact of Ixazomib in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in Russia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pin42 - Determinating the Acceptable Price for Quadrivalent Influenza Vaccine in Russia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Low-Dose Lenalidomide and Dexamethasone Combination Treatment in Elderly Patients With Relapsed and Refractory Multiple Myeloma
Hematology
Hematology
Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study
American Journal of Hematology
Hematology
Phase I/Ii Trial of Bendamustine, Ixazomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Pcn88 - Net Impact Analysis of Ixazomib in Combination With Lenalidomide and Dexamethasone in the Treatment of Adults With Multiple Myeloma for Quebec
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Pcn173 - Cost-Effectiveness of New Triplet Combinations With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Lenalidomide Plus Dexamethasone Is More Effective Than Dexamethasone Alone in Patients With Relapsed or Refractory Multiple Myeloma Regardless of Prior Thalidomide Exposure
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Optimizing the Use of Lenalidomide in Relapsed or Refractory Multiple Myeloma: Consensus Statement
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
